Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aquestive Therapeutics stock

Learn how to easily invest in Aquestive Therapeutics stock.

Aquestive Therapeutics is a drug manufacturers-specialty & generic business based in the US. Aquestive Therapeutics shares (AQST) are listed on the NASDAQ and all prices are listed in US Dollars. Aquestive Therapeutics employs 157 staff and has a trailing 12-month revenue of around $48.1 million.

How to buy Aquestive Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – AQST. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Aquestive Therapeutics stock price (NASDAQ: AQST)

Use our graph to track the performance of AQST stocks over time.

Aquestive Therapeutics shares at a glance

Information last updated 2023-02-01.
Latest market close$0.88
52-week range$0.62 - $3.19
50-day moving average $0.92
200-day moving average $1.06
Wall St. target price$5.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.75

Buy Aquestive Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Aquestive Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aquestive Therapeutics price performance over time

Historical closes compared with the close of $0.8799 from 2023-02-01

1 week (2023-01-27) -0.76%
1 month (2023-01-03) -2.22%
3 months (2022-11-03) 2.05%
6 months (2022-08-03) 5.00%
1 year (2022-02-01) -69.02%
2 years (2021-02-03) -84.43%
3 years (2020-02-03) 3.95
5 years (2018-01-30) N/A

Aquestive Therapeutics financials

Revenue TTM $48.1 million
Gross profit TTM $35.8 million
Return on assets TTM -45.91%
Return on equity TTM 0%
Profit margin -147.69%
Book value $-2.00
Market capitalisation $48.2 million

TTM: trailing 12 months

Aquestive Therapeutics share dividends

We're not expecting Aquestive Therapeutics to pay a dividend over the next 12 months.

Aquestive Therapeutics share price volatility

Over the last 12 months, Aquestive Therapeutics's shares have ranged in value from as little as $0.618 up to $3.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aquestive Therapeutics's is 2.725. This would suggest that Aquestive Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aquestive Therapeutics overview

Aquestive Therapeutics, Inc. , a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc.

Frequently asked questions

What percentage of Aquestive Therapeutics is owned by insiders or institutions?
Currently 2.429% of Aquestive Therapeutics shares are held by insiders and 29.456% by institutions.
How many people work for Aquestive Therapeutics?
Latest data suggests 157 work at Aquestive Therapeutics.
When does the fiscal year end for Aquestive Therapeutics?
Aquestive Therapeutics's fiscal year ends in December.
Where is Aquestive Therapeutics based?
Aquestive Therapeutics's address is: 30 Technology Drive, Warren, NJ, United States, 07059
What is Aquestive Therapeutics's ISIN number?
Aquestive Therapeutics's international securities identification number is: US03843E1047
What is Aquestive Therapeutics's CUSIP number?
Aquestive Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03843E104

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site